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Abstract: Systemic presence of arthritis autoantibodies (AAb) is specific for rheumatoid arthritis
(RA). AAb initiation might be triggered by chronic mucosal inflammation, such as in inflammatory
bowel disease (IBD). We assessed the prevalence of anti-citrullinated protein antibodies (ACPA) and
rheumatoid factor (RF) in ulcerative colitis (UC) and Crohn’s disease (CD) patients, with regard to the
prevalence of joint complaints in AAb+ versus AAb− IBD patients. RA patients and healthy subjects
(HC) served as controls. Serum was collected from 226 UC, 165 CD and 86 RA patients, and 36 HCs.
One-hundred-and-ten UC (48.7%) and 76 CD (46.1%) patients were seropositive for at least one
autoantibody, compared to 4 (13.9%) HCs and 81 (94.2%) RA patients. Eighty-three (37%) UC and 52
(32%) CD patients were seropositive for the anti-cyclic citrullinated protein antibody (anti-CCP2) of
the immunoglobulin A type (IgA anti-CCP2), compared to 1 (2.8%) HC and 64 (74%) RA patients.
RF of the immunoglobulin G type (IgG RF) and IgA RF seropositivity in UC and CD patients was
comparable to HCs and low compared to RA patients. Arthralgia was reported by 34 (18.7%) UC and
50 (33.1%) CD patients, but presence of arthralgia was not increased in AAb+ patients. AAbs are
frequently present in IBD patients, supporting the hypothesis that inflammation of intestinal mucosa
induces low systemic levels of ACPA.
Keywords: rheumatoid arthritis; inflammatory bowel disease; ulcerative colitis; Crohn’s disease;
anti-citrullinated protein antibodies; arthralgia
1. Introduction
Inflammatory bowel disease (IBD) is characterized by inflammation of the intestinal mucosa.
Ulcerative colitis (UC) and Crohn’s disease (CD) are the main subtypes. UC and CD differ in the
location and nature of the disease [1,2]. UC is usually characterized by involvement of the colon with
acute and chronic inflammation limited to the mucosa, while inflammation can be transmural in any
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part of the gastrointestinal tract in CD patients. Extra-intestinal manifestations are often present in UC
and CD patients, of which peripheral arthropathy is most commonly observed [2–4].
Certain antibodies have been described to be present in UC and CD patients. UC is associated
with the presence of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) [5], while CD is
characterized by antibodies against microbes such as Saccharomyces cerevisiae (ASCA). Both antibodies
were found to have a high specificity but a rather low sensitivity for UC and CD, which hampers
their clinical utility. However, the presence of these autoantibodies is associated with a more severe
disease phenotype in UC and CD [6]. These antibodies can already be present in serum years before
the diagnosis of UC or CD is made [7].
An important hallmark for rheumatoid arthritis (RA) is the presence of rheumatoid factor (RF) and
anti-citrullinated protein antibodies (ACPA), the latter being the most specific for RA [8,9]. The role
of these autoantibodies in RA pathogenesis is currently unclear, but their presence in RA patients is
associated with a more severe disease outcome [10]. Furthermore, RA is often preceded by the presence
of these autoantibodies years before the clinical onset [11].
During inflammation, when apoptosis and necrosis take place, citrullination of proteins occurs in
the intestinal tissue of IBD patients [12,13]. Citrullinated proteins are generated via the conversion
of arginine into citrulline by a posttranslational process mediated by the enzyme peptidyl arginine
deiminase (PAD). Citrullinated epitopes are created during this process, which might be targeted
by ACPA, a phenomenon that also occurs in RA. Therefore, the initiation of ACPA production has
been hypothesized to take place at inflamed mucosal surfaces in predisposed individuals, e.g., in the
gastrointestinal tract [14,15], via PAD release by neutrophils, or exposure to citrullinated proteins by
neutrophil extracellular traps (NETs) [16]. This hypothesis is supported by the capability of plasma
cells in inducible bronchus-associated lymphoid tissue from RA patients to produce ACPA locally [17].
In the current study, we measured the serological levels of ACPA (of the immunoglobulin A (IgA)
and immunoglobulin G (IgG) type) and RF (IgM and IgA) in a cross-sectional group of IBD patients. It
is reported in the literature that IgA ACPA [18,19] and IgG ACPA [20–22] have a low prevalence in IBD
patients. None of these studies assessed the presence of low ACPA levels below the diagnostic cut-off,
however. Diagnostic cut-off means the level that is used for diagnosis of the RA. For the IgG anti-cyclic
citrullinated protein antibody (anti-CCP2), this level is 25 U/mL when using the commercial anti-CCP2
ELISA (Enzyme-Linked Immuno Sorbent Assay). We presume that a rise of ACPA levels compared
to healthy controls, even below diagnostic cut off, might indicate the initiation of ACPA production.
Therefore, the objective of this study was to assess whether IgA ACPA, IgG ACPA, IgA RF and IgG
RF were present in IBD patients (UC and CD) as well as to assess the prevalence of arthropathies,
especially the presence of arthralgia, in autoantibody positive and autoantibody negative IBD patients.
The combination of the presence of ACPA and/or RF and arthralgia has been shown to increase the risk
for future RA development [15,23].
2. Materials and Methods
2.1. Patients
A total of 391 IBD patients (226 patients with UC and 165 with CD) participating in the Dutch
IBD Pearl Chain Institute Biobank Initiative were included. All patients gave their informed consent
before study enrollment. Patients were included when there was a confirmed diagnosis for UC
or CD. Patients were examined by a gastroenterologist at the outpatient clinic of the University
Medical Center Groningen, who asked about the presence of arthralgia. The diagnosis of arthritis and
spondylarthropathies needed to be confirmed by a rheumatologist. Blood was withdrawn at study
enrollment and serum was stored at −80 ◦C until further use. Clinical and demographic information,
including age, gender, diagnosis, duration of disease, body mass index (BMI), and smoking habits were
standardized and recorded at the time of blood withdrawal. Serological parameters, such as pANCAs,
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anti-ASCA (IgA and IgG), C-Reactive Protein (CRP) levels and erythrocyte sedimentation rate (ESR)
were routinely measured. CRP was measured by turbidimetry with a lower limit of detection ≤3 mg/L.
An HC group (n = 36), consisting of persons without systemic disease [24], was included to define
cut off-levels for autoantibody levels. Additionally, 86 RA patients were included as a reference group
for serological measurements. The study was conducted with the approval of the Medical Ethics
Committee of the University Medical Center Groningen.
2.2. Laboratory Measurements
Anti-cyclic citrullinated protein antibody (anti-CCP2) levels were measured using the commercial
anti-CCP2 ELISA (Eurodiagnostica). The manufacturer’s protocol was adjusted to measure specifically
low IgG anti-CCP2 levels as earlier described [16]. Samples were diluted 1:10 instead of 1:50 in dilution
buffer. Seropositivity was defined as >2SD above the mean of HC (2.2 U/mL).
The specific ACPA response of the 20 IBD patients with the highest IgG anti-CCP2 levels
was measured with ELISA by testing the reactivity against 4 well-known citrullinated antigens,
which are often recognized by ACPA from RA patients. These well-known citrullinated antigens
were two peptides from fibrinogen (Fib1, β-chain amino acids 36–52, NEEGFFSACitGHRPLDKK
and Fib2, β-chain amino acids 60–74, CitPAPPPISGGGYCitACit), one peptide from α-enolase (Eno1,
KIHACitEIFDSCitGNPTVE), and one peptide from vimentin (Vim1, VYATCitSSAVCitLCitSSV).
Citrulline-specific IgG reactivity was determined by measuring the difference in reactivity against
the citrullinated and native form of the peptides, with the cut-off defined as the difference in optical
density (∆OD) >2SD above the mean of HCs, as previously described [24].
IgA anti-CCP2 levels were measured using a modified anti-CCP2 assay. Sera were diluted
1:50 using the dilution buffer provided by the manufacturer. Bound human IgA was detected by
the secondary antibody horseradish peroxidase (HRP)-conjugated polyclonal goat anti-human IgA
(SouthernBiotech, Birmingham, AL, USA), diluted in phosphate-buffered saline (PBS) with 1% bovine
serum albumin (BSA) and 0.05 % Tween-20 (Sigma-Aldrich, St. Louis, MO, USA). The color reaction
was performed using tetramethylbenzidine (Sigma-Aldrich) and hydrogen peroxide. A pool of sera
from 4 RA-patients with high IgA anti-CCP2 levels served as a calibrator for the standard curve
expressed in arbitrary units per milliliter (AU/mL) and starting at 200 AU/mL. Seropositivity was
defined as >2 SD above the mean of HCs.
IgM and IgA RF levels in serum were measured by a validated in-house ELISA assay [25].
Levels were expressed in international units per milliliter (IU/mL), and seropositivity was defined as
>10 IU/mL for IgM RF and >25 IU/mL for IgA RF.
2.3. Statistical Analysis
Statistical analysis was performed with GraphPad Prism software (version 5.00 for Windows,
GraphPad Software, La Jolla, CA, USA) and IBM SPSS Statistics for Windows software (version 20.0,
IBM, Armonk, NY, USA). For group comparisons, a Mann–Whitney U test was used for continuous
variables, and Fisher’s exact test or Chi-square test for categorical variables. Values of p < 0.05 were
considered to be significant.
3. Results
3.1. General Characteristics
The demographic and clinical characteristics of patients and healthy controls are depicted in
Table 1. UC patients had a significantly higher BMI than CD patients (p = 0.001), while the CD-cohort
was comprised of more (ever) smokers than the UC cohort (p = 0.009). The disease duration was
similar in both groups.
Int. J. Environ. Res. Public Health 2020, 17, 8054 4 of 10




















Female, n (%) 20 (55.6) 60 (70) 123 (54.4) 105 (63.6) 0.077
Age, years, mean, (SD) 34 (15) 55 (11) 42 (15) 41 (15) 0.606
BMI, kg/m2, mean, (SD) a – – 26.1 (4.6) 24.8 (4.9) 0.001
Current or ever smoker, n (%) b 8 (22.3) 34 (39) 129 (57.1) 108 (67.1) 0.006
DAS28, median, IQR – 2.2 (1.7–2.8) – – –
Disease duration, years, (median, IQR) – 5.5 (3–10) 7 (4–13) 9 (4–16) 0.037
Montréal classification
Age at diagnosis, n (%) c 0.092
A1 below 16 years – – 20 (9.0) 26 (16.2)
A2 between 17 and 40 years – – 146 (65.8) 101 (62.7)
A3 above 40 years – – 56 (25.2) 34 (21.1)
Disease extent (E) and severity
(S) in UC, n (%) d
E1 ulcerative proctitis – – 37 (17.0) – –
E2 left sided UC – – 74 (33.9) – –
E3 extensive UC – – 107 (49.1) – –
S0 clinical remission – – 20 (9.3) – –
S1 mild UC – – 68 (31.8) – –
S2 moderate UC – – 72 (33.6) – –
S3 severe UC – – 54 (25.2) – –
Disease location (L) and
behavior (B) in CD, n (%) e
L1 ileal – – – 57 (36.3) –
L2 colonic – – – 32 (20.4) –
L3 ileocolonic – – – 67 (42.7) –
L4 isolated
upper disease – – – 1 (0.6) –
B1 non-stricturing,
non-penetrating – – – 83 (51.2) –
B2 stricturing – – – 56 (34.6) –
B3 penetrating – – – 23 (14.2) –
P perianal
disease modifier – – – 45 (27.8) –
a 225/226 UC and 164/166 CD; b 161/165 CD; c Age known for 222/226 UC and 161/165 CD; d According to
Montréal classification, A (age at diagnosis), E (Extent) known for 218/226 and S (Severity) known for 214/226 UC;
e L (Location) known for 157/165 CD and B (Behavior) known for 162/165 CD. Analysis: Mann–Whitney U test for
continuous variables and Fisher exact or Chi-Square test for categorical variables. BMI, body mass index; DAS28,
Disease Activity Score 28, tender and swollen joint count.
3.2. Autoantibody Seropositivity
Overall, IgG anti-CCP2 levels were low when the diagnostic value in RA diagnosis was taken into
account (25 U/mL). In contrast to the RA patients, none of the IBD patients displayed levels above the
diagnostic cut-off value of RA, with the highest level being 13.6 U/mL in the IBD patients. However,
when seropositivity was defined using a lower cut-off, >2SD above the mean of HCs, 29 UC patients
(13%) and 28 CD patients (17%) were seropositive for IgG anti-CCP2, while 2 (5.6%) HCs and 74
(86%) RA patients were seropositive. Additionally, the specific IgG response against four citrullinated
peptides (Fib1, Fib2, Eno1 and Vim1) was measured in 20 sera from IBD patients with the highest IgG
anti-CCP2 response, all being higher than 4 U/mL. None of these IBD patients showed citrulline-specific
reactivity against any of these four peptides. Therefore, citrulline-specific reactivities against these
peptides were not measured in any of the other IBD patients, as no positive results were to be expected.
IgA anti-CCP2 levels are generally not used in RA diagnosis, therefore no diagnostic cut-off is
known. When applying a similar cut-off, as was used for IgG anti-CCP2, >2SD above the mean of
HCs, 83 UC patients (37%) and 52 CD patients (32%) were seropositive for IgA anti-CCP2, while only 1
(2.8%) HC and 64 (74%) RA patients were.
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IgM and IgA RF seropositivity was low with 10 (4.4%) patients being seropositive for IgM RF,
6 (2.7%) for IgA RF in UC patients, 6 (3.6%) for IgM RF, and 8 (4.8%) in CD patients, respectively,
compared to 1 the (2.8%) in HCs for both IgM RF and IgA RF. 64 (74%) and 43 (50%) RA patients were
seropositive for IgM RF and IgA RF, respectively.
In total, 110 UC patients (48.7%) and 76 CD patients (46.1%) were seropositive for at least one
arthritis autoantibody, of which the majority were positive for IgA anti-CCP2. The autoantibody levels
are shown in Figure 1, while seropositivity in the groups is depicted in Figure 2.
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Figure 1. Arthritis Autoantibody (AAb) levels for healthy controls (HC, n = 36), Ulcerative colitis 
(UC, n = 226), Crohn’s disease (CD, n = 165) and rheumatoid arthritis (RA, n = 86) patients. (A) IgG 
anti-CCP2 levels; (B) IgA anti-CCP2 levels; (C) IgM RF levels and (D) IgA RF levels. U/ml = Units/ml; 
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Figure 1. Arthritis Autoantibody (AAb) levels for healthy controls (HC, n = 36), Ulcerative colitis
(UC, n = 226), Crohn’s disease (CD, n = 165) and rheumatoid arthritis (RA, n = 86) patients. (A) IgG
anti-CCP2 levels; (B) IgA anti-CCP2 levels; (C) IgM RF levels and (D) IgA RF levels. U/mL = Units/mL;
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and CD (n = 76) patients, represented i pie charts.
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3.3. Rheumatic Manifestations and Arthritis Autoantibody Status
Next, IBD patients who were seropositive for any of the arthritis autoantibodies (AAb+) were
compared to arthritis autoantibody negative (AAb−) IBD patients on clinical manifestations (Table 2).
Over 90% of AAb+ patients were seropositive for IgA and/or IgG anti-CCP2. AAb+ and AAb− patients
did not differ in smoking behavior, disease duration or disease activity. AAb+ positive patients were
significantly younger than AAb− patients (UC p = 0.016, CD p = 0.017). AAb+ UC patients were
significantly younger at the disease onset than AAb− UC patients (p = 0.021). CRP levels higher than
3 mg/L were seen in 21% of AAb− UC patients and 22% of AAb+ UC patients, while this level was
18% in AAb− CD patients and 38% in AAb+ CD patients. ESR (p = 0.009) and CRP (p = 0.008) levels
were significantly increased in AAb+ CD patients compared to AAb− CD patients.
Table 2. Comparison between serological characteristics and articular manifestations in inflammatory
bowel disease (IBD) patients subdivided for seropositivity for at least one rheumatoid arthritis (RA)
related autoantibody.











(n = 76) p Value
Female, n (%) 67 (57.8) 56 (50.9) 0.35 55 (61.8) 50 (65.8) 0.624
Age, years, mean (SD) 44.1 (15) 39.4 (14) 0.016 43.6 (15) 38.0 (14) 0.017
Ever smoker, n (%) 70 (60.3) 59 (53.6) 0.348 60 (69.0) 48 (64.9) 0.616
Active disease, n (%) a 34 (29.3) 35 (31.8) 0.661 39 (47.6) 29 (42.7) 0.622
Age at diagnosis, n (%) 0.021 0.159
A1 below 16 years 9 (7.8) 11 (10.3) 10 (11.2) 16 (22.2)
A2 between 17 and 40 years 68 (59.1) 78 (72.9) 60 (67.4) 41 (56.9)
A3 above 40 years 38 (33.0) 18 (16.8) 19 (21.3) 15 (20.8)
Disease duration, years, median (IQR) 7 (4–14) 7 (4–12) 0.425 11 (4–17) 8.5 (4–15) 0.264
ESR, mm/h, median (IQR) 11 (5–18) 11 (5–18) 0.974 9 (5–20) 17.5 (8–24) 0.009
CRP, mg/l, median (IQR) ≤3 (≤3–3) ≤3 (≤3–3) 0.865 ≤3 (≤3–3) ≤3 (≤3–8) 0.008
pANCA, seropositive (%) b 51 (52.7) 54 (61.4) 0.239 20 (25.6) 18 (29.5) 0.702
ASCA, seropositive (%) c 24 (25.8) 24 (27.3) 0.867 48 (61.5) 40 (69.0) 0.582
Arthropathies
Enthesitis, n 0 1 - 3 0 -
Arthritis, n 0 0 - 0 1 -
Inflammatory backpain, n 0 0 - 3 0 -
Arthralgia, n (%) d 13 (14.7) 21 (22.3) 0.254 26 (32.5) 24 (34.3) 0.863
AAb−, arthritis autoantibody negative; AAb+, arthritis autoantibody positive; a measured by simple clinical colitis
activity index (SCCA) ≥3 or Harvey-Bradshaw index ≥4; b known for 180/226 UC and 139/165 CD; c Defined as IgA
and/or IgG ASCA seropositive, known for 181/226 UC and 136/165. d known for 182/226 UC and 151/165 CD; A, age at
diagnosis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; pANCA, Perinuclear Anti-Neutrophil
Cytoplasmic Antibodies; ASCA, anti-Saccharomyces cerevisiae antibodies.
The presence of arthralgia was reported in 34 (18.7%) UC-patients and 50 (33.1%)
CD-patients. Remarkably, in AAb+ IBD patients, the presence of arthralgia was not increased.
Articular manifestations other than arthralgia were reported in few patients not allowing for any
statistical analysis. Treatment in UC and CD consisted of (a combination of) immunosuppressive
drugs, mesalazine, steroids, azathioprine, methotrexate, and anti-Tumor Necrosis Factor (TNF) agents.
Anti-CCP2 and/or RF seropositivity was not associated with any of these therapies.
4. Discussion
Inflamed mucosal surfaces (e.g., intestinal tissue, lungs and periodontium) have been hypothesized
as sites where the formation of ACPA initiates. The lungs [17,19] and periodontium [26,27] have
already been studied as potential sites for AAb generation, while the intestinal area is still to be assessed
as a site where autoantibody generation starts. The current study revealed that AAbs, especially
ACPA of both IgA and IgG subclasses, are present in serum from IBD patients. ACPAs, especially of
the IgA subclass, are increased in IBD patients compared to HCs, but do not exceed the diagnostic
level for RA [24]. IgM RF and IgA RF seropositivity was comparable to that observed in the general
population [28]. With regard to IBD patients with arthralgia, AAb+ IBD patients were significantly
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younger; the implications of this observation is not straightforward and was unexpected, as AAb
positivity is more prevalent among the aged [29]. The higher ESR and CRP levels in AAb+ than
in AAb− CD patients confirm the hypothesis that low positive ACPA levels are associated with
inflammation. Although CD and UC are both inflammatory diseases, CRP is a less reliable marker of
inflammation and disease activity in patients with UC, perhaps except for severe, extensive colitis [30].
Environmental and genetic factors are thought to play a role in the development of ACPA.
Environmental factors such as smoking were shown as risk factors for developing ACPA-positive
RA [15,31,32]. Smoking is considered to induce ACPA via the citrullination of proteins in the lungs by
activating the enzyme peptidyl arginine deiminase (PAD). Our results showed that the AAb− and
AAb+ IBD patients did not differ in smoking behavior. The presence of citrullinated proteins in colonic
biopsies from IBD patients [12,33] might be on the basis of the higher systemic ACPA levels in IBD
patients, similarly as smoking is able to induce citrullination in the lungs [34].
Genetic factors for ACPA development in RA, especially human leukocyte antigen DR beta 1
(HLA-DRB1) shared epitope (SE) alleles, are thought to play a role in the epitope spreading and rise
of ACPA levels after the initiation of ACPA production, which is HLA-DRB1 SE independent [35].
In addition, bacterial antigens are hypothesized to contribute to ACPA development via molecular mimicry
of self-antigens presented by predisposing HLA-DQ molecules [36]. However, HLA-associated genetic
risk factors involved in IBD [37,38] are not involved in development of ACPA+ RA [39]. Therefore,
we can speculate that due to the absence of these HLA-related risk factors, ACPA initiation in IBD is
not followed by a maturation of the ACPA response and spreading of epitopes, which can be measured
in the context of RA development. This is also reflected by the negative results on the reactivity against
the four citrullinated peptides, although this assay is also less sensitive than the anti-CCP2 ELISA.
The results of our study show that extra-intestinal manifestations in IBD patients are not associated
with arthritis autoantibody levels in serum. The presence of arthralgia was reported in a high number
of patients (34 (18.7%) UC patients and 50 (33.1%) CD patients). Arthralgia was not clearly defined;
therefore, it could have been that enthesitis and fibromyalgia were also in part responsible for these
large numbers. Notwithstanding, our study confirms the results of other studies that found no
association between articular manifestations and ACPA in IBD patients [21,22,40].
IBD is a condition which is particularly linked to gut microbiota, especially to gammaproteobacteria
and the presence of Escherichia coli and fusobacteria [41–44]. The link between RA and the human
microbiome is less clear [45]. The oral anaerobe bacterium Porphyromonas gingivalis has been
hypothesized to play a role in RA development by creating citrullinated bacterial and/or human
antigens with its own PAD-enzyme (PPAD) [46]. However, oral microbiome studies [47,48] did not find
associations with P. gingivalis in the oral microbiome and the presence of RA. Thus, enzymatic activity of
PPAD is probably not a major virulence mechanism during the early stages of inflammatory arthritis [49].
Studies on gut-microbiota in treatment-naive RA patients point towards an increased prevalence of
Prevotella copri in early RA patients [50] as well as Lactobacillus salivarius [48]. Zhang et al [48] studied
the relationship between the gut microbiome and autoantibody levels and found that Haemophilus spp.
were negatively correlated with anti-CCP, while the presence of Prevotella spp. positively correlated
with RF. Whether gut-microbiota also play a role in articular manifestations and autoantibody levels in
IBD patients remains a topic for future research.
A limitation of the current study was that not all UC and CD patients were seen by a rheumatologist.
Only in case of a suspect of arthritis and spondylarthropathies was the patient seen by a rheumatologist.
Another limitation of the study was that we could not relate arthritis autoantibodies to gut microbiome data,
which would have been very interesting, since such an association has been suggested in several studies.
5. Conclusions
In conclusion, arthritis autoantibodies are present in serum from IBD patients, which supports the
hypothesis that the inflammation of intestinal mucosa induces low systemic levels of ACPA, although
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their role in the induction of RA is yet unclear. The development of arthralgia in IBD patients is
independent of the presence of arthritis autoantibodies.
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